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Summary 
Background: Human papilloma virus is a common sexually transmitted viral infection that affects both men and 
women with an overall prevalence of cytology given as 21.8% for women.  
Objective: The main objective of the study was to determine the healthcare worker’s perception on the HPV 
vaccines at Nairobi Women’s Hospital and Mbagathi District Hospital in Nairobi, Kenya.  
Materials and methods: The study which was carried out in Mbagathi district hospital and Nairobi Women’s 
hospital was a descriptive cross sectional which utilized both quantitative and qualitative techniques. Self-
administered questionnaire was done to 107 participants while key informant interviews were conducted 
amongst the in-charges of the facilities. Data from the questionnaire was entered into a computer using EXCEL 
and exported to Social Package for Social Sciences (SPSS) for analysis. Comparisons between the two 
hospitals were done using chi-square (Fishers exact test) for categorical variables. Logistic regression analysis 
was performed to determine factors influencing perception of healthcare workers on HPV vaccine. The level of 
statistical significance was 5%. Data from the interviews were manually sorted out based on themes developed 
from the responses in line with the objectives and are presented verbatim. 
Results: Health workers at Nairobi Women were 1.3 times more likely to report knowledge that HPV is sexually 
transmitted compared to their colleagues at Mbagathi (RR = 1.3, 95% CI 1.1-1.4, p 0.005). 87.7% of health 
workers in Mbagathi and 97% at Nairobi Women’s recognised that HPV was associated with cervical cancer 
and there was no significant differences in knowledge of the association between HPV infection and cancer at 
the two hospitals (RR = 1.1, 95% CI 0.99-1.3). Health workers at Nairobi women’s predominantly reported that 
HPV causes cancer of the cervix (RR = 5.0, 95% CI 2.9-8.7, p < 0.001). Those at Nairobi women’s were likely 
to report that HPV predisposes infected individual to cancer of the cervix (RR = 0.1, 95% CI 0.1-0.4, p < 
0.001). There were no differences in attitude towards vaccination in terms of recommending HPV to clients 
(81.8% versus 81.1%) and recommending or receiving vaccine if funding was made available to subsidise HPV 
vaccine costs (93.9% versus 82.4%).  
Conclusions and recommendations: The knowledge, perceptions and the practices of health workers relating to 
HPV are largely dependent upon the sector (private or public), availability of vaccine, policies and not on their 
level of education and the professional training thereof. There is need to empower healthcare workers in public 
health facilities by providing information, prioritizing the availability and the acquisition of the vaccines in an 
attempt to improve their perception and practices. 
[Afr J Health Sci. 2016; 29(1):69-75]  
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Introduction 
Human papilloma virus is a common sexually 
transmitted virus which affects both men and women 
with condoms partially effective in preventing infection 
as any exposed skin can transmit the virus (1). HPV is 
responsible for other benign genital infections such as 
recurrent juvenile respiratory papillomatosis and genital 
warts, both mainly caused by HPV types 6 and 11(2). 
Human papilloma virus is commonly found in the 
anogenital tract with or without clinical lesions. The 
prevalence of HPV increases with severity of the lesion. 
Majority of the approximately 200 known types of HPV 
do not cause any symptoms in most people. More than 
30 types of HPV are typically transmitted through 
sexual contact and infect the anogenital region. Some 
types can cause warts, while others can lead to cancers 
of the cervix, vulva, vagina and anus in women or 
cancers of the anus and penis in men.  
HPV is a member of the papillomaviridae family of 
viruses. Papillomaviruses are small DNA viruses, 
approximately 52-55nm in diameter.  There are more 
than 100 types of HPV.  Worldwide HPV- 16 and 18 
contribute to over 70% of all cancer cases. The most 
prevalent type of HPV worldwide is type 16 with less 
variation in geographical distribution than other types 
(3). Studies done have shown that the overall 
prevalence of any HPV types in the general population 
of Sub Saharan Africa for women with normal cytology 
is 21.8%. The prevalence of HPV types 16 and 18 
among ICC cases in SSA range from 43.7 to 90.2%. 
The overall combined estimated HPV 16 and 18 
prevalence among ICC cases in Mozambique was 
found to be 69% (4), which is consistent with worldwide 
estimates of 70% (5). 
HPV is a risk factor for cervical cancer, however it is 
not the only one necessary for progression from cervical 
HPV infection to cancer. Other risk factors include 
tobacco smoking, high parity, long-term hormonal 
contraceptive use, and co-infection with HIV have been 
identified as established cofactors. Co-infection with 
Chlamydia trachomatis and herpes simplex virus type-
2, immunosuppression, and certain dietary deficiencies 
are other probable cofactors. Genetic and 
immunological host factors and viral factors other than 
type, such as variants of type, viral load and viral 
integration, are likely to be important but have not been 
clearly identified (6). 
A strong association has been found between presence 
of HPV and the occurrence of cervical cancer (7,8). 
Among the 15 high-risk oncogenic HPV genotypes that 
have been identified, HPV 16 and 18 have been 
associated with most of the HPV-associated cervical 
cancer cases (9,10). HPV types 16, 18, 31 and 45 are 
called "high-risk" types because they can lead to 
cervical, anal, vulvar, penile, and lung cancers. 
Cervical cancer is the second leading cause of cancer 
death in women globally and the first in many 
developing countries. In sub Saharan Africa cervical 
cancer is the most common cancer (11).  In Kenya, 
according to the Nairobi cancer registry, cervical cancer 
accounted for 19.3% of all cancer cases recorded in 
the period 2003-2006. Accordingly, cervical cancer is 
the most frequent cancer amongst women with mortality 
of 2111 lives every year (12). 
Cervical cancer cytology screening programmes have 
been successful in curbing the incidence of cervical 
cancer in developed countries (13). Screening 
programmes coverage in Sub-Saharan Africa has been 
shown to be very low, between 0.4%-20.2% (14). 
Many women in developing countries still do not get 
screened with women seeking medical attention when 
cancer is at an advanced stage, leading to higher 
mortality as treatment options may not be successful 
with advanced disease (15). 
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Routine pap smear tests can be done to detect early 
lesions of the disease. It is estimated that 70,722 new 
cases of invasive cervical cancer occur annually in sub-
Saharan Africa and it is responsible for one quarter of 
all female cancers (16). In East Africa the age-
standardized incidence rate of cervical cancer is 42.7 
per 100,000 women (17). In contrast, the age 
standardized incidence rates is 12.1 in North America 
and 11.9 in Europe (12). Each year, approximately 
450,000 new cases of invasive cervical cancer have 
been reported to be diagnosed worldwide, with the rate 
being highest in regions where there is little cytological 
cervical cancer screening (18).  
HPV vaccines are part of the primary cervical cancer 
prevention tools. Vaccines targeting high-risk HPV 
types and other types may be used to create immunity 
to HPV thus enhancing prevention of cervical cancer 
(12). This may be an effective tool towards reducing 
the burden of cervical cancer disease. Commercial 
vaccines against HPV 16 and HPV 18 have been made 
available though global variations in HPV type specific 
prevalence could affect their effectiveness (19). 
However, the vaccines do not treat existing infections or 
lesions and so are recommended for young women 
without known exposure to targeted types of HPV (20). 
Most countries that have issued official 
recommendations for immunization recommend 
immunization of pre-adolescent girls of age 9-13years 
(21). In the USA, girls aged 11-12years have been 
reported to be the target for vaccination (22). In Kenya, 
the guidelines for HPV vaccines are in preparation 
stage and the vaccines have been made available in 
limited hospital set-ups.  
Kenya became the first country to protect girls in Kitui 
with free of charge vaccine under The Global Access to 
Vaccines Initiative (GAVI) supported ‘record low price’ 
in May 2013 to developing countries which included 
Kenya (23). Under that initiative, girls were given free 
vaccines.  In 2010, the cost of either the quadrivalent 
HPV vaccine (Gardasil®) or the bivalent HPV vaccine 
(Cervarix®) was about US$400 (24).  This is out of 
reach to many young women in Kenya, thus the 
importance of international agencies to assist with the 
cost of HPV vaccine or the need for lower-cost 
vaccines. The vaccines secured by GAVI was costing 
$4.50 (about Kshs 5,000) a dose while it cost more 
than $100 (about Kshs 10,000) a dose in developed 
countries (23). 
Although that was the situation, a study in Kisumu (25) 
showed that ninety-five percent (95% CI: 92%, 99%) 
responded that they were likely to have their daughters 
immunized if the vaccine protected against cervical 
cancer, 94% (95% CI: 90%, 98%) were likely to have 
their daughters immunized if the vaccine protected 
against genital warts, and 95% (95% CI: 92%, 99%) 
were likely to have their daughters immunized if the 
vaccine protected against both cervical cancer and 
genital warts. This was only if the vaccine was availed 
and made free of charge. 
However, HPV vaccines have been made available in 
Kenya for clinical use. The uptake and acceptance of 
the vaccine depends largely upon and whether 
providers recommend the vaccines to the target 
population. The introduction of the vaccines has 
positioned healthcare workers to play an active role in 
ensuring its successful implementation. Healthcare 
workers are the first line in promotion of HPV vaccines 
to parents of target group for vaccines. The positive 
role of physicians has been acknowledged as important 
to the acceptability of vaccinations among parents (26). 
A study done in Italy showed that paediatricians were 
found to be the providers of most of information on HPV 
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vaccine (31%) and were perceived as preferred 
immunization providers (77%) (27). In Canada it was 
found that 95% of respondents in a survey on health 
care providers knowledge, attitudes and beliefs about 
HPV vaccination indicated that the vaccine should be 
given to girls before onset of sexual activity. Eighty 
percent of the respondents felt that the best age for 
vaccination is < 14years (1). The cost of vaccines may 
affect the clinical staff’s attitudes towards 
recommending the vaccines as shown in a survey 
where majority of respondents intended to recommend 
HPV vaccine if they are publicly funded (28).  
Healthcare workers interact with patients a lot during 
patient’s clinical care.  They are the ones who 
administer vaccines and so are very important in terms 
of uptake of HPV vaccines. 85% of respondents on a 
survey done on nurses’ knowledge, attitudes and 
practices on HPV vaccines acknowledged that they 
would recommend HPV vaccines to their patients (27). 
Another study done found that a personal belief in the 
positive impact of the HPV vaccine and providers 
feeling comfortable talking with parents about sexual 
nature of vaccine as the most common factors 
influencing perceptions (29).  
 
Results  
Socio-demographic characteristics of healthcare 
workers 
Table 1 below shows that 30.7% of the healthcare 
workers were recruited from Nairobi Women’s hospital 
and 69.2% from Mbagathi Hospital. The average age of 
participants was 28.5 years (sd 7.6). Overall, 37.4% of 
health workers were aged between 23 and 24 years 
with this age group being the modal age group both 
within Mbagathi hospital (33.8%) and Nairobi Women’s 
hospital (45.5%).  Female healthcare workers 
accounted for 67.3% and the percentage of participants 
at the two hospitals were not significantly different 
(63.5% in Mbagathi compared to 75.8% in Nairobi 
Women’s Hospital. 
71% healthcare workers held diploma qualifications 
(Mbagathi Hospital (67.6%) versus (78.8%) in Nairobi 
Women’s hospital). However, there were more 
healthcare workers who held first degree in Mbagathi 
Hospital (21.6%) compared to Nairobi Women’s 
hospital (15.2%). There were significant differences in 
the duration of service (in years) reported at the two 
hospitals (chi square = 9.8, d.f = 2; P value = 0.008). 
Most healthcare workers at both sites had been in 
service for less than 5 years (59.5% versus 66.7%). A 
higher percentage of staff in Mbagathi hospital 
compared to Nairobi Women’s hospital had served for 
at least 11 years (29.7% versus 6.1%). 
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Table 1: Demographic characteristics of health workers
 
 Hospital  
Totaln (%) Variable Mbagathi DH-n (%) Nairobi Women’s- n (%) 
Age in years    
23-24 25(33.8) 15(45.5) 40(37.4) 
25-29 20(27.0) 11(33.3) 31(29.0) 
30-34 7(9.5) 6(18.2) 13(12.2) 
35-39 10(13.5) 1(3.0) 11(10.3) 
40-44 7(9.5) 0 7(6.5) 
45-49 5(6.8) 0 5(4.7) 
Sex    
Male 27(36.5) 8(24.2) 35(32.7) 
Female 47(63.5) 25(75.8) 72(67.3) 
Education qualification    
Diploma 50(67.6) 26(78.8) 76(71.0) 
Higher diploma 8(10.8) 1(3.0) 9(8.4) 
Bachelors degree 16(21.6) 5(15.2) 21(19.6) 
Masters degree 0 1(3.0) 1(1.0) 
Duration of service in years    
0-5 44(59.5) 22(66.7) 66(61.7) 
6-10 8(10.8) 9(27.3) 17(15.9) 
11 and above 22(29.7) 2(6.1) 24(22.4) 
 
Distribution of healthcare workers by cadre 
Further, figure 1 below shows that Nairobi Women’s 
hospital had a higher percentage (18.2%) of doctors 
compared to Mbagathi District hospital (5.4%). It is 
important to note that whereas Mbagathi had (24.3%) 
clinical officers, Nairobi Women had no clinical officers. 
Overall, nurses comprised the majority (73.8%) of 
healthcare workers, and were also the majority in 
Mbagathi (70.3%) and Nairobi Women’s’ (81.2%). 
 
 
 
Figure 1: Distribution of healthcare workers by cadre 
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Healthcare workers on HPV Vaccine  
Table 2 below shows that all (100%) the healthcare 
workers at Nairobi Women had heard about the vaccine 
compared to 71.6% at Mbagathi with 75% and 44.6%, 
respectively, having heard about them in 
college/university. Most health workers in Mbagathi 
(97%) and Nairobi Women (87.8%) recognised that 
HPV was associated with cervical cancer and there was 
no significant differences in knowledge of the 
association between HPV infection and cancer at the 
two hospitals (RR = 1.1, 95% CI 0.99-1.3). However, 
the healthcare workers differed in the perception of the 
mechanism of HPV association with cancer of the 
cervix. Healthcare workers at Mbagathi Hospital 
predominantly reported that HPV causes cancer of the 
cervix (RR = 5.0, 95% CI 2.9-8.7, p < 0.001), 
compared to their colleagues at Nairobi women’s 
hospital while healthcare workers at Nairobi Women’s 
hospital were likely to report that HPV predisposes 
infected individual to cancer of the cervix (RR = 0.1, 
95% CI 0.1-0.4, p < 0.001).  
 
Table 2:  Knowledge on HPV vaccine 
Knowledge   Hospital Total 
n (%) 
RR (95% CI) P value 
Mbagathi 
n (%) 
Nairobi women’s 
n (%) 
Ever heard about HPV vaccine 53(71.6) 33 (100) 86(80.4) 1.4 (1.2-1.6) 0.0001 
Heard about vaccine in:      
College/ university  33(44.6) 24(75) 57(69.5) 1.6 (1.2-2.3) 0.007 
Workshop/ CME 11(22) 7(21.9) 18(22) 1.4 (0.6-3.4) 0.418 
Journal/ Magazine 6(12) 1(3.1) 7(8.6) 0.4 (0.05-2.9) 0.327 
Attended CME on HPV 28(37.8) 29(88.9) 57(53.3) 2.3 (1.7 – 3.2) <0.001 
Cervical cancer  and HPV      
HPV associated with cervical 
cancer 
32(97) 65(87.8) 97(90.7) 1.1 (0.99-1.3) 0.134 
HPV causes cervical cancer 27(83.4) 11(17) 38(39.2) 5.0 (2.9-8.7) <0.001 
HPV predisposes to cervical cancer  5(15.6) 54(83) 59(60.8) 0.2(0.1-0.4) <0.001 
 
Knowledge on HPV vaccine according to cadre 
All the participating doctors (100%) had reported that 
they had ever heard of HPV vaccine compared to 
77.2% and 83.3% of nurses and Clinical Officers, 
respectively. Doctors were also more likely to have 
heard about the vaccine during undergraduate training 
(80%) compared to nurses (48.1%) and Clinical 
Officers (61.1%). Nurses (48.1%) reported attending 
CMEs on HPV more recently than other cadres 
(27.8%-30%). At least one-half of health workers in 
each cadre reported that HPV predisposes individuals 
to cervical cancer with most (77.8%) clinical officers 
reporting knowledge of HPV predisposing individuals to 
cervical cancer (Table 3 below). 
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Table 3: Knowledge on HPV vaccine according to cadre 
 Health worker cadre 
 Doctor Nurse  CO 
Ever heard about HPV vaccine 10(100.0) 61(77.2) 15(83.3) 
Heard about vaccine in:    
College/university training 8(80.0) 38(48.1) 11(61.1) 
Workshop/CME 1(10.0) 13(16.5) 4(22.2) 
Journal/magazine 1(10.0) 6(7.6) 0(0.0) 
Attended CME on HPV    
0-6 months 3(30.0) 38(48.1) 5(27.8) 
6mths-1yr 0(0.0) 4(5.1) 0(0.0) 
1-2yrs 1(10.0) 1(1.3) 1(5.6) 
more than 2 years 1(10.0) 0(0.0) 3(16.7) 
Cervical cancer  and HPV    
HPV causes cervical cancer 3(30.0) 33(41.8) 2(11.1) 
HPV predisposes someone to cervical cancer 5(50.0) 40(50.6) 14(77.8) 
 
Responses on the affected age group 
Figure 3 shows most health workers at both Mbagathi 
and Nairobi Women indicated that cervical cancer was 
most commonly found in the age groups 21 to 40 
years, followed by the age group 41 to 60 years.  
Figure 3: Comparison on age group affected by cervical cancer 
 
 
 
 68 
African Journal of Health Sciences, Volume 29, Number 1, January-February 2016 
Perceptions and practices of healthcare workers 
towards HPV vaccines 
Table 4 shows practices and attitudes related to HPV 
vaccines among health workers at Mbagathi and Nairobi 
Women’s hospital. Attitudes measured by question on 
whether healthcare workers were willing to get 
vaccinated, recommend the vaccine or receive the 
vaccine if HPV was funded. The responses showed that 
with the exception of willingness to get vaccinated 
under current conditions where healthcare workers in 
Nairobi Women had a more positive attitude (93.9% 
versus 43.2%), there were no differences in attitude 
towards vaccination in terms of recommending HPV to 
clients (81.8% versus 81.1%) and recommending or 
receiving vaccine if funding were made available to 
subsidise HPV vaccine costs (93.9% versus 82.4%). 
In regard to practices health workers at Nairobi Women 
were more likely to report having received HPV vaccine 
(69.7% versus 2.7%), administered (87.9% versus 
4.1%) and recommended (87.9% versus 17.6%) HPV 
vaccine to a client compared to health workers at 
Mbagathi. 
 
Table 4:  Perceptions and practices of healthcare workers towards HPV vaccine  
Question/issue Hospital Yes  No  Not sure 
Would you get vaccinated with HPV 
vaccine? 
Nairobi Women’s  31(93.9) 0 2(6.1) 
Mbagathi DH 32(43.2) 17(23) 25(33.8) 
Would you recommend the vaccine to a 
client? 
Nairobi Women’s  27(81.8) 0 6(18.2) 
Mbagathi DH 60(81.1) 3(4.1) 11(14.8) 
Would you recommend/receive the 
vaccine if it is funded hence cheaper? 
Nairobi Women’s  31(93.9) 0 2(6.1) 
Mbagathi DH 61(82.4) 6(8.1) 7(9.5) 
Have you received the HPV Vaccine at 
the hospital? 
Nairobi Women’s  23(69.7) 10(30.3) NA 
Mbagathi DH 2(2.7) 72(97.3) NA 
Have you administered the vaccine to a 
patient? 
Nairobi Women’s  29(87.9) 4(12.1) NA 
Mbagathi DH 3(4.1) 71(95.9) NA 
Have you already recommended the 
vaccine to a client? 
Nairobi Women’s  29(87.9) 4(12.1) NA 
Mbagathi DH 13(17.6) 61(82.4) NA 
 
Willingness of the healthcare workers to be 
vaccinated with vaccine 
Table 5 below shows that 60% of nurses and doctors 
compared to (50%) of Clinical Officers were willing to 
get vaccinated with HPV vaccine. Most health workers 
across the different cadres would recommend the 
vaccine to clients both at the market price and if the 
vaccine price was subsidized. Less than one-third of 
doctors (20%), nurses (29.1%) and Clinical Officers 
(0%) had received the vaccine in the hospital. (40%) of 
doctors had administered the vaccine to a client 
compared to (34.2%) of nurses and (5.6%) of Clinical 
Officers.   
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Table 5: Perceptions and practices towards HPV vaccine according to cadre of healthcare worker 
Issues 
Cadre of healthcare worker  
Doctors Nurses CO 
Would get vaccinated with HPV vaccine 6(60.0) 48(60.8) 9(50.0) 
Would recommend the vaccine to a client 7(70.0) 63(79.7) 17(94.4) 
Would  recommend/receive the vaccine if it is funded 
hence cheaper 7(70.0) 71(89.9) 14(77.8) 
Had received the HPV Vaccine at the hospital 2(20.0) 23(29.1) 0(0.0) 
Had administered the vaccine to a patient 4(40.0) 27(34.2) 1(5.6) 
Had already recommended the vaccine to a client 5(50.0) 31(39.2) 6(33.3) 
 
Perception of healthcare workers on Vaccines 
The perception of the healthcare workers on HPV 
vaccines was assessed using qualitative data collected 
from open-ended questions administered to all 107 
participating health workers and additional data from in-
depth key informant interview among health workers (n 
= 10) in-charge of different services.  The 10 key 
informants included medical officers (n = 2), a clinical 
officer and nurses (n = 8). This is shown in table 6 
below. 
Table 6: Perceptions of heath workers on HPV vaccines at Nairobi Women’s and Mbagathi 
Perception/issue 
Nairobi 
Women's 
n = 33 
MDH 
n =  74 
Total 
n = 107 
Reasons for not getting HPV vaccination    
Not aware of vaccine 1(3%) 6(8.1%) 7(6.5%) 
Not well informed on 0(0%) 11(14.9%) 11(10.3%) 
Fear of side effects 0(0%) 1(1.4%) 1(0.9%) 
Cost of vaccine 1(3%) 5(6.8%) 6(5.6%) 
Availability of vaccine 2(6.1%) 4(5.4%) 6(5.6%) 
Don’t know 0(0%) 2(2.7%) 2(1.9%) 
Reasons for not recommending HPV to client    
Cost of vaccine 27(81.8%) 12(16.2%) 39(36.4%) 
Fear of side effects 0(0%) 3(4.1%) 3(2.8%) 
Not well informed 2(6.1%) 21(28.4%) 23(21.5%) 
Vaccine schedule 0(0%) 1(1.4%) 1(0.9%) 
Availability of vaccine 1(3%) 18(24.3%) 19(17.8%) 
Other 0(0%) 1(1.4%) 1(0.9%) 
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Reasons why health workers have never received HPV 
at Hospital    
Not aware of vaccine 2(6.1%) 12(16.2%) 14(13.1%) 
Not well informed on HPV 2(6.1%) 17(23%) 19(17.8%) 
Fear of side effects 0(0%) 1(1.4%) 1(0.9%) 
Cost of vaccine 1(3%) 8(10.8%) 9(8.4%) 
Availability of vaccine 1(3%) 14(18.9%) 15(14%) 
Don’t know 0(0%) 1(1.4%) 1(0.9%) 
Reason why health workers have never administered 
vaccine    
Not aware of vaccine 2(6.1%) 16(21.6%) 18(16.8%) 
Not well informed on HPV 0(0%) 6(8.1%) 6(5.6%) 
Fear of side effects 0(0%) 2(2.7%) 2(1.9%) 
Cost of vaccine 0(0%) 1(1.4%) 1(0.9%) 
Availability of vaccine 1(3%) 36(48.6%) 37(34.6%) 
Don’t know 0(0%) 2(2.7%) 2(1.9%) 
 
Discussion 
East Africa has been highlighted as having the highest 
incidence of invasive cervical cancer in the world (30). 
In this regard, highly effective prophylactic vaccines 
against HPV-16 and -18, have been made available 
for use in many countries. HPV vaccines have been 
recognized and recommended by WHO as an integral 
way of preventing cervical cancer (12,31,32).  Many 
countries including Kenya have put up strategies 
towards the implementation and realization of 
prophylactic HPV vaccination. This saw Kenya 
becoming the first nation among the developing 
countries to protect girls with free vaccines in 2013 
under the GAVI initiative. HPV vaccines have been 
shown to prevent infections by certain types of human 
papillomavirus associated with the development of 
cervical cancer, genital warts, and other cancers 
(33,24). There are two vaccines (Gardasil and 
Cervarix) in the market, which have been approved for 
use in many countries as of 2014 (34). Both vaccines 
protect against the two HPV types (HPV-16 and HPV-
18) which has been shown to cause 70% of cervical 
cancers, 80% of anal cancers, 60% of vaginal cancers 
and 40% of vulvar cancers (35). 
However, this study has found out that the uptake of 
health services in any facility is largely dependent upon, 
among other factors, the efficient manner in which 
healthcare workers relate clients’ assessments to the 
type of treatment to be prescribed and administered. 
This ability is informed by the overall knowledge 
(acquired through experience or education by 
perceiving, discovering, or learning) of the healthcare 
workers on recognizing and handling patients up-to 
administering the right drugs. Many a times a gap in 
knowledge may be witnessed amongst health workers 
in as far as acceptance, priority setting and other issues 
related to new interventions is concerned Further, the 
success of any integrated service has been shown in a 
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study to be related to several factors, including 
knowledge, understanding and preferences of health 
workers and the community members (33). 
 
This study shows that 58.1% of respondents in 
Mbagathi indicated that cervical cancer mostly affects 
individuals between age 21-40years whereas 12.2% of 
respondents did not know the age distribution of 
cervical cancer in the population. All the healthcare 
workers (100%) in Nairobi Women’s hospital perceived 
that there is an association between HPV infection and 
cervical cancer while 91.9% of those in Mbagathi had 
the same understanding. Further, this study found that 
75.5% of the healthcare workers at Mbagathi were not 
aware of  the types of HPV vaccines available in Kenya 
while 87.1% at Nairobi Women’s reported knowing one 
commercially available vaccine. This can be attributed 
to the availability and accessibility of the vaccines at the 
respective hospitals. The vaccines are not available at 
Mbagathi while they are stocked at Nairobi Women’s 
hospital. 30% and 33.3% of healthcare workers at 
Nairobi Women’s hospital perceived 0-5 and 26-
30years respectively as being appropriate age for target 
group vaccination while 31% of Mbagathi district 
hospital respondents perceived 16-20years as being 
appropriate age for vaccination. This finding is similar to 
that of another study done in western Kenya where 
focused group discussions were done with caregivers 
and opinion leaders (40). 
In addition, this study has shown that 46% of all 
respondents knew of a specific vaccine and 25% 
mentioned cervarix when asked to specify the HPV 
vaccine known to them. This shows that there is no 
sufficient knowledge on HPV and HPV vaccines among 
the respondents. A study in Mulago hospital, in 
Uganda, whose objective was to describe knowledge on 
cervical cancer found that 93% considered cancer of 
the cervix a public health problem and knowledge about 
Pap smear was 83% among respondents (41).  Worth 
noting also is the finding of this study that 69% of 
healthcare workers had heard of HPV and the vaccine 
during training either at university or college with only 
21% and 9% having heard of the same through 
workshops and journals respectively.  
Findings of this study demonstrated that healthcare 
workers can, with that knowledgeable background, be 
able to detect HPV and subsequently treat it soonest 
before it can lead to cervical cancer. The primary goal 
in HPV vaccination is to prevent cervical cancer. 
Although the importance of the Pap smear in reducing 
cancer incidence and mortality is known, many 
developing countries especially in Africa have not 
mounted national cervical cancer screening programs. 
However, Kenya took up the initiative to provide 
universal HPV immunization in 2013 (14). 
This study has shown that all participants (100%) at 
Nairobi Women’s hospital were aware that HPV is a 
sexually transmitted virus and knew of existence of 
vaccines for HPV as compared to those at Mbagathi 
hospital where 84.7% of respondents knew that HPV is 
a sexually transmitted virus and 71.4% had heard of 
the vaccine. This finding (which is similar to another 
finding by [36]   shows that healthcare workers in 
private health facilities seem to be more aware of the 
HPV vaccine as well as knowing that HPV is a sexually 
transmitted virus. This could be attributed to many 
issues that support the same in the private sector. For 
instance, the private health sector such as the Nairobi 
Women’s hospital, is providing all health services using 
the latest interventions as their procurement plans are 
not subjected to numerous and tedious bureaucracies 
witnessed in public health facilities such as at Mbagathi 
district hospital. 
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The practices of the healthcare workers towards HPV 
varied between the two hospitals. Most respondents in 
Nairobi Women’s hospital reported having received 
(79.3%), administered the vaccine (93.6%) and 
recommended (93.6%) to patients. In Mbagathi hospital 
on the other hand only 2.8% reported having received 
the vaccine with only 4% having administered the 
vaccine while 18.9% had recommended the vaccine. 
One respondent observed; 
“You see, we only administer what we have in 
our stores” 
 
This could be attributed to the fact that the vaccine is 
not available more often in public hospitals and or lack 
of marketing of the vaccines to the public facilities. This 
is further shown in this study where the greatest barrier 
to HPV uptake as perceived by healthcare workers was 
availability and accessibility of the vaccine in Mbagathi 
in contrast to what was found out at the Nairobi 
Women’s Hospital where the vaccine was noted to be 
readily available. This study found that where 
healthcare workers reported availability of the vaccine at 
the hospital there were concerns on the affordability and 
this hampered accessibility of the vaccines. This finding 
concurs with findings in a study in Hong Kong which 
showed that 68.3% of the respondents agreed that 
HPV vaccination be fully paid by the government as an 
important public health strategy (37).  
Despite studies that have shown a clear link between 
HPV and cervical cancer, HPV vaccines have not been 
widely accessible and affordable both to the healthcare 
workers and the beneficiaries. Other issues such as 
lack of awareness and stigma associated with cancer 
pose a real threat to accessing HPV vaccines despite 
WHOs’ recommendation in 2009 that routine HPV 
vaccination be included in national immunization 
programs. Cancer is however preventable through 
vaccination and effective screening. The emergence of 
HIV has been shown in a study to exacerbate HPV 
infection, which can develop into cervical cancer more 
quickly in women living with HIV than in women who 
are HIV negative (38). However, this study found out 
that the greatest barrier to HPV uptake as perceived by 
health workers was availability and accessibility of the 
vaccine, as noted by one health worker; 
“Aki, kupatikana kwa hii chanjo kwa zahanati 
hasa za umma ni ngoma na ikipatikana inakuwa 
ni kwa gharama kubwa sana (truly, getting this 
vaccine especially in public facilities is a tall 
order and if they are available it’s at big price)  
This study also found out that lack of prioritization and 
clarity on government policy concerning HPV use and 
ordering problems at hospital level and the overall 
procurement of HPV vaccine was attributed to the 
unavailability of the vaccine in public facilities, as noted 
by one respondent; 
“You know how commodities and other supplies 
are procured..This is a tedious process where 
commodities may get late in reaching facilities, 
thus missing the need of getting them to needy 
populations” 
The Kenya Medical Supplies Agency (KEMSA), 
established as a state corporation under Cap 446, is a 
specialized Government medical logistics provider for 
Ministry of Health-supported health facilities and 
programmes in Kenya. One of its main tasks is to play 
a key role in procuring, storing and distributing health 
commodities for the public sector. Vaccine procurement 
is a specialized field that is different from the 
procurement of other pharmaceuticals and health 
products in several ways. Despite some similarities to 
other pharmaceuticals, this study found out that 
vaccines possess a number of peculiarities, which 
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require specific consideration during the procurement 
process.  
Healthcare workers interviewed were cognizant of the 
critical role of the perceptions of the healthcare workers 
in influencing uptake of the vaccine with all the 
respondents indicating a need for training on HPV and 
HPV vaccines within their institutions. One respondent 
noted;  
“The healthcare worker is a strong pillar 
regarding the utilization of this essential service 
is concerned and their perceptions are always 
very critical and important” 
Lack of information on the HPV vaccine was found out 
to be a major issue among healthcare workers at 
Mbagathi DH and not Nairobi Women’s Hospital. A 
respondent at Nairobi Women’s noted; 
“We have sufficient information on HPV 
vaccine…thanks to the hospital management 
which made it possible to get them” 
This lack of information influenced perception of the 
vaccine in Mbagathi and was cited as an important 
reason, which hampered the recommendation of HPV 
vaccine by healthcare workers to clients, and vaccine 
administration. However, at Nairobi Women’s hospital 
this study found out that healthcare workers had 
adequate information on HPV vaccine. This result is 
similar to findings of a study done in Nyanza where it 
was noted that success of HPV vaccination would 
depend critically on information, communication and 
social mobilisation of healthcare workers (39).  
Though the level of education was not a significant 
factor in influencing the perceptions of the health 
workers on the HPV vaccines, there was no significant 
difference in the levels of education at the two health 
facilities. Nurses accounted for between 52% and 59% 
of the respondents at the two facilities.  
There was a significant difference (p=0.001) in ages of 
respondents at the two facilities. The average age of 
respondents at Nairobi Women’s was 25.9% while at 
Mbagathi  hospital average age was 30.3%  with none 
of the participants at Nairobi Women’s being above 
40years of age. This study has therefore shown that 
age is a key influencing factor on perceptions of 
healthcare workers on the HPV vaccines.  
Healthcare worker attitude and their level of awareness 
were both found out in this study as potential enablers 
and barriers to HPV uptake depending on the whether 
workers displayed positive or negative attitude or 
whether they had adequate or inadequate knowledge 
about the vaccine.  
 
Conclusions  
The polices and the management practices in the 
private sector have been noted to greatly influence 
certain  aspects including how the health workers 
perceptions and practices relating to work and 
particularly in as far as the acquisition of HPV is 
concerned.  This study has noted that though Kenya 
provided universal HPV immunization in 2013, the 
vaccines can be accessed easily in a private health 
facility (Nairobi Women) than in the public facility like 
Mbagathi. 
The attitudes and practices of the healthcare workers 
and the general uptake of HPV vaccine are influenced 
by many factors that include the availability of vaccine 
and policies and lack of information. Moreover, there is 
a discrepancy in the level of perception and practices 
towards HPV among health workers in public and 
private health facilities with those in the private sector 
having more levels on all the issues. 
 
 
 
 African Journal of Health Sciences, Volume 29, Number 1, January-February 2016 
 
 
72 
Recommendations 
To be able to reach out to many needy populations, 
there is need to prioritize the availability and the 
acquisition of the vaccines especially to the public 
health facilities at the community level for optimal 
utilization in order to realize the desired target of 
alleviating un-necessary suffering and the pain 
associated with their health concerns are addressed. 
Given the importance of the vaccine and the association 
of HPV with several cancers the government should 
step in with other partners such as GAVI to make the 
vaccine available probably through inclusion in the KEPI 
program. The management policies that govern public 
health sector should therefore be targeted for revision to 
fasten acquisition of the vaccines, among other health 
services. 
In an attempt to improving on the perceptions and the 
overall practices of the health workers both in the 
private and public sectors on HPV, there should be 
intentional efforts by the government through the 
ministry of health to continue providing and supporting 
refresher courses, educative seminars or set resources 
towards training them on the health expectations 
associated with HPV.  
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